Chad Robins, CEO of Adaptive Biotechnology.
Anjali Sundaram CNBC
Simon Barnett, an analyst at Ark Invest, explained Monday the company’s focus on what it calls the genomic revolution, breaking down two of its favorite funds: Adaptive Biotechnologies and Invitae
In an interview with CNBC’s “Closing Bell,” Barnett said Cath Invest, led by Cathie Wood, sees great potential for investors in the branch of molecular biology known as genomics, which considers it “one of the opportunities most transformative investment of the century “.
Ark’s fund family includes the Genomic Revolution ETF (ARKG), which seeks to offer investors exposure to areas such as DNA sequencing technology and molecular diagnosis.
ARKG has fallen by about 7% so far.
However, in the last twelve months, the ETF has increased by approximately 160%. The firm’s flagship fund is Ark Innovation ETF (ARKK), which has fallen by approximately 1.6% so far in 2021. ARKK has also risen almost 160% in the last 12 months.